Menu Search
Equities

Bioventix PLC

BVXP:LSE

Bioventix PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)3,710.00
  • Today's Change-40.00 / -1.07%
  • Shares traded1.81k
  • 1 Year change-4.87%
  • Beta0.2807
Data delayed at least 20 minutes, as of Nov 21 2024 16:24 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast in GBX

The one analyst offering a 12 month price target expects Bioventix PLC share price to rise to 5,100.00 in the next year from the last price of 3,710.00.
High37.5%5,100.00
Med37.5%5,100.00
Low37.5%5,100.00

Dividends

In 2024, Bioventix PLC reported a dividend of 1.55 GBP, which represents a 1.97% increase over last year. The analyst covering the company expects dividends of 1.60 GBP for the upcoming fiscal year, an increase of 3.23%.
Div growth (TTM)1.97%
More ▼

Earnings history & estimates in GBX

Bioventix PLC reported annual 2024 earnings of 152.86 per share on Oct 28, 2024.
Average growth rate+2.96%
More ▼

Revenue history & estimates in GBP

Bioventix PLC had revenues for the full year 2024 of 13.61m. This was 6.17% above the prior year's results.
Average growth rate+7.18%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.